Literature DB >> 27081281

Erythema Annulare Centrifugum: Analysis of Associated Diseases and Clinical Outcomes according to Histopathologic Classification.

Dae Hong Kim1, Ji Hyun Lee1, Jun Young Lee1, Young Min Park1.   

Abstract

Entities:  

Year:  2016        PMID: 27081281      PMCID: PMC4828397          DOI: 10.5021/ad.2016.28.2.257

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


× No keyword cloud information.
Dear Editor: Erythema annulare centrifugum (EAC), a chronic inflammatory skin disease with an unknown etiology, is considered a hypersensitivity reaction caused by cutaneous or systemic infection, malignant neoplasms, drugs, and various autoimmune diseases, among other factors12. Clinically, EAC presents as erythematous papules or plaques that enlarge by peripheral extension with central clearing, resulting in an annular or polycyclic appearance13. Kim et al.3 previously reported that EAC is associated with various underlying conditions, including infectious and immunologic diseases, consumption of certain food, and drug use. Furthermore, Weyers et al.4 suggested that, although EAC is generally classifiedas either superficial or deep, the term should be reserved for the superficial type only, as these types appear to be separate clinicopathologic entities, and the deep type should hence be classified as another disease entity. Meanwhile, Ziemer et al.5 concluded that EAC is a clinical reaction pattern rather than a specific clinicopathologic entity. As mentioned above, histopathologically, based on the extent of perivascular lymphocytic infiltration, EAC can be divided into superficial and deep types. However, according to this histopathologic classification, the clinical characteristics are currently not fully understood. Thus, the purpose of this study was to analyze the clinical features, associated diseases, recurrence rates, and treatment outcomes of EAC according to the histopathologic subtypes. We retrospectively analyzed the medical records and biopsy specimens of 39 patients histopathologically diagnosed with EAC at the Department of Dermatology at the Catholic Medical Center (Seoul, Korea) between January 2003 and December 2013. The Institutional Review Board of the Catholic Medical Center granted approval (XC14RIMI0086) for the review of the medical records, and the study protocol was conducted in accordance with the Helsinki Declaration of 1975 (as revised in 2000). Associated diseases were confined to cases that occurred before the development of EAC and that showed a correlation with the clinical course of EAC. We divided the treatment outcomes into three groups: (1) excellent (>50% improvement in the skin lesion within 3 months after treatment), (2) moderate (took more than 3 months to achieve >50% improvement after treatment), and (3) poor (<50% improvement at 3 months after treatment)6. Recurrence was defined as skin lesions showing aggravation after an excellent response. We reviewed the histopathologic slides of the patients, and classified the cases that presented with various epidermal changes (hyperkeratosis, parakeratosis, spongiosis, or basal vacuolar degeneration) and perivascular lymphocyte infiltration in the upper dermis into superficial EAC. In contrast, cases that showed no or minimal epidermal changes, mild edema in the papillary dermis, and perivascular inflammatory cells (lymphocyte predominant) in the upper and deep dermis were classified as the deep type. Data analysis was conducted using IBM SPSS Statistics ver. 22.0 (IBM, Armonk, NY, USA). For categorical data, χ2 or Fisher's exact test was used as appropriate. A p-value<0.05 was considered statistically significant. Among the 39 patients, 13 patients (33.3%) showed associated conditions, including cutaneous fungal infection (n=5), pregnancy (n=2), malignancy (thyroid cancer, n=2), autoimmune diseases such as Behcet disease and rheumatoid arthritis (n=2), and medication use (cephalosporin, n=2). Based on the histopathologic findings, 32 cases (82.1%) were classified into the superficial type, and 7 cases (17.9%) into the deep type (Table 1).
Table 1

Demographic and clinical data of 39 patients with erythema annulare centrifugum

Patient no.Sex/age (yr)SiteAssociated conditionPathologic typeRecurrenceResponse to treatmentContinuous duration (mo)
1F/39Both ankles-SuperficialExcellent1.9
2F/37ButtockTinea corporis, tinea pedisSuperficial-Moderate7.0
3F/29Whole bodyPregnancySuperficialPoor3.0
4F/38Abdomen and extremity-Deep-Moderate7.0
5M/41Trunk and right thighBehcet diseaseDeep-Poor>23.0
6F/65Abdomen and both legsThyroid cancer, tinea corporis, onychomycosisSuperficial-Poor14.0
7M/25Whole bodyDrug use (cephalosporin)Superficial-Excellent1.0
8M/66Right arm and leg-Superficial-Excellent1.0
9M/10 moButtockDrug use (cephalosporin)Superficial-Excellent1.0
10F/33Both legs and arms-SuperficialModerate1.3
11M/25Trunk-SuperficialExcellent0.9
12F/34Both legs-Superficial-Moderate7.0
13F/34Both legs-SuperficialUKUKUK
14F/40Buttock-Deep-Excellent1.5
15M/40Back-Superficial-Excellent1.0
16F/30Right leg-SuperficialExcellent2.0
17M/40Right arm-Superficial-Moderate4.0
18F/30Right armTinea corporisSuperficial-Excellent2.0
19M/38Right arm-SuperficialModerate2.0
20F/34Right arm-Superficial-Excellent0.8
21M/50Right thighSeborrheic dermatitisSuperficial-Moderate2.0
22F/52Right legRheumatoid arthritisSuperficial-Poor>17.0
23F/35Trunk and thighPregnancySuperficial-Poor>21.0
24F/41Trunk-SuperficialUKUKUK
25F/55Right thigh-DeepUKUKUK
26M/41Both legsTinea pedisSuperficialUKUKUK
27F/33Abdomen-SuperficialUKUKUK
28F/24Trunk and neck-SuperficialUKUKUK
29M/61Trunk and both arms-SuperficialUKUKUK
30F/27Right knee-SuperficialUKUKUK
31F/37Back-SuperficialUKUKUK
32M/66Trunk and thighTinea corporisDeep-Moderate7.0
33M/65Trunk-SuperficialUKUKUK
34F/52Extremities-SuperficialUKUKUK
35F/41Whole body-DeepUKUKUK
36M/53Trunk-Superficial-Poor12.0
37F/53Extremities-SuperficialExcellent1.7
38F/27ButtockThyroid cancerSuperficial-Poor>8.0
39F/26Right leg-Deep-Excellent2.0

M: male, F: female, UK: unknown.

Twenty-seven (superficial type, n=22; deep type, n=5) of the 39 patients had available follow-up data from our clinic after the skin biopsy, and their clinical outcomes were as follows: 5 patients (18.5%) showed persistent skin lesions without improvement (poor response) over 1 year. The average duration of continuous skin lesionswas 4.7 months. Thirteen (48.1%), 7 (25.9%), and 7 patients (25.9%) showed the excellent, moderate, and poor responses, respectively. Of the 7 cases with a poor response, 1 and 6 cases were deep and superficial EAC, respectively. Eleven of the 32 superficial cases (34.4%) were associated with another disease, whereas 2 out of the seven deep cases (28.6%) had associated diseases. These results indicated that there were no remarkable differences in the incidence rates of associated diseases between the superficial and deep types of EAC (p=1) (Table 1). However, a distinct difference between the superficial and deep types was observed for the average duration of continuous skin lesions (4.1 vs. 8.1 months). The recurrence rate was 31.8% for the superficial type, whereas no deep EACs showed recurrence. In terms of treatment outcomes, 27.3% and 20.0% of patients with the superficial and deep types respectively revealed a poor response to treatment; there was little difference between these two types (p=0.965) (Table 2).
Table 2

Clinical features of erythema annulare centrifugum according to histopathologic classification

VariableSuperficialDeepp-value
Recurrence, n (%)7/22 (31.8)0/5 (0)
Average continuous duration (mo)4.18.1
Response to treatment (%)0.965
 Excellent50.040.0
 Moderate22.740.0
 Poor27.320.0
There were some limitations to this study, including the fact that it was a retrospective study and that the number of deep-type cases was small. Accordingly, further large-scale prospective studiesare required to ascertain these results. In conclusion, our findings revealed differences in the clinical outcomes according to the histopathologic subtype of EAC, with the superficial type being associated with a higher recurrence rate and a shorter duration of skin lesions compared with the deep type.
  5 in total

1.  Erythema annulare centrifugum associated with chronic lymphocytic leukaemia.

Authors:  I Helbling; R Walewska; M J S Dyer; M Bamford; K E Harman
Journal:  Br J Dermatol       Date:  2007-11       Impact factor: 9.302

2.  Severe and refractory solar urticaria treated with intravenous immunoglobulins: a phase II multicenter study.

Authors:  François Aubin; Raphaël Porcher; Michel Jeanmougin; Fabienne Léonard; Christophe Bedane; Anne Moreau; Jean-Luc Schmutz; Marie-Claude Marguery; Henri Adamski; Manuelle Viguier
Journal:  J Am Acad Dermatol       Date:  2014-08-16       Impact factor: 11.527

3.  Clinicopathologic analysis of 66 cases of erythema annulare centrifugum.

Authors:  Kyoung Jin Kim; Sung Eun Chang; Jee Ho Choi; Kyung Jeh Sung; Kee Chan Moon; Jai Kyoung Koh
Journal:  J Dermatol       Date:  2002-02       Impact factor: 4.005

4.  Erythema annulare centrifugum: results of a clinicopathologic study of 73 patients.

Authors:  Wolfgang Weyers; Carlos Diaz-Cascajo; Imke Weyers
Journal:  Am J Dermatopathol       Date:  2003-12       Impact factor: 1.533

5.  New concepts on erythema annulare centrifugum: a clinical reaction pattern that does not represent a specific clinicopathological entity.

Authors:  M Ziemer; K Eisendle; B Zelger
Journal:  Br J Dermatol       Date:  2008-08-20       Impact factor: 9.302

  5 in total
  7 in total

1.  Erythema annulare centrifugum triggered by SARS-CoV-2 infection.

Authors:  N Setó-Torrent; A Altemir; M Iglesias-Sancho; M T Fernández-Figueras
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-09-15       Impact factor: 9.228

2.  Recurrent Erythema Annulare Centrifugum due to Influenza Type A.

Authors:  Luca Ena; Vittorio Mazzarello; Marco Ferrari; Pasquale Ena
Journal:  Case Rep Dermatol       Date:  2021-02-18

3.  Paraneoplastic erythema annulare centrifugum associated with mycosis fungoides.

Authors:  Hannah J Thompson; Brian J King; Brian Link; Vincent Liu
Journal:  JAAD Case Rep       Date:  2021-10-05

Review 4.  NRF2 in dermatological disorders: Pharmacological activation for protection against cutaneous photodamage and photodermatosis.

Authors:  Shirin Kahremany; Lukas Hofmann; Arie Gruzman; Albena T Dinkova-Kostova; Guy Cohen
Journal:  Free Radic Biol Med       Date:  2022-06-23       Impact factor: 8.101

5.  More data on erythema annulare centrifugum induced by COVID-19 vaccination.

Authors:  Alexander Kreuter; Jimmy Jos Puthussery; Julia Hyun; Valentina Laura Müller
Journal:  Dermatol Ther       Date:  2022-06-21       Impact factor: 3.858

6.  Erythema annulare centrifugum in a case of chronic myeloid leukemia.

Authors:  Prabhat Agrawal; Amit Kumar; Nikhil Pursnani; Geetika Agarwal; Satyanand Sathi
Journal:  J Family Med Prim Care       Date:  2022-06-30

7.  A 78-Year-Old Female with a Diffuse Pruritic Rash and Palmoplantar Desquamation.

Authors:  Gabriel E Molina; Melissa J Danesh; Ruth K Foreman; Daniela Kroshinsky
Journal:  Dermatopathology (Basel)       Date:  2020-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.